-
Tiny Molecules May Tell Big Story about Cardiovascular Disease Risk
Tiny bits of molecular “trash” found in circulating blood appear to be good predictors of cardiovascular disease and untimely death, say researchers at Duke University Medical Center.
Feb. 22, 2010
-
Low-Carb Diet Effective at Lowering Blood Pressure
In a head-to-head comparison, two popular weight loss methods proved equally effective at helping participants lose significant amounts of weight. But, in a surprising twist, a low-carbohydrate diet proved better at lowering blood pressure than the weight-loss drug orlistat.
Jan. 25, 2010
-
A DASH of Exercise and Weight Loss Improves Blood Pressure
Adding exercise and weight loss to the nationally recommended DASH diet (Dietary Approaches to Stop Hypertension) reduced blood pressure equal to rates expected with use of medication alone, according to researchers at Duke University Medical Center.
Jan. 25, 2010
-
New Test May Predict Heart Disease Events and the Effect of Weight Loss on Insulin Resistance
Chemical fingerprints produced by the body’s normal metabolic processes predict who will suffer cardiovascular events and who will benefit from weight loss by reduction of insulin resistance, according two new studies by researchers at Duke University Medical Center.
Nov. 17, 2009
-
New Heart Pump Extends Life of Heart Failure Patients
In one of the largest studies conducted to date, a new heart pump, or left ventricular assist device (LVAD), demonstrated a four-fold increase in the survival of advanced heart failure patients without a stroke or device failure.
Nov. 17, 2009
-
Duke Heart Center Receives American College of Cardiology Foundation Performance Achievement Award
Duke Heart Center at Duke University Hospital (DUH) has received the American College of Cardiology Foundation’s NCDR ACTION Registry–GWTG Gold Performance Achievement Award for 2009 -- one of only 121 hospitals nationwide to do so.
Nov. 17, 2009
-
New Anti-Clotting Medication Not More Effective than Standard Care; Hint of Other Clinical Benefits
Two large studies confirmed that an investigational, reversible anti-clotting medication failed to show greater effectiveness than clopidogrel or a placebo for patients undergoing a procedure to open blocked coronary arteries, according to researchers at the Duke Clinical Research Institute. However, some data in the study suggest the potential for a different, more targeted use for cangrelor.
Nov. 16, 2009
-
Duke Clinical Research Institute to Begin Nationwide Outcomes Study of Atrial Fibrillation Treatment
To address the need for more information to help improve the care of patients with atrial fibrillation, the Duke Clinical Research Institute (DCRI) is launching the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). ORBIT-AF is a prospective, longitudinal, observational study, scheduled to begin in December, which will evaluate treatment patterns and the subsequent outcomes of 10,000 patients in the United States.
Nov. 11, 2009
-
Newer Anti-Clotting Medication Found to Be More Effective
A large head-to-head study of two anti-clotting medications for heart patients has found that the investigational compound ticagrelor (Brilinta) was more effective at reducing cardiovascular death than the current standard of care, clopidogrel (Plavix), according to researchers at Duke University Medical Center.
Aug. 30, 2009
-
Gender Differences Explain Death Rates Following a Heart Attack
One of the largest studies exploring heart attack-related gender differences found that women are twice as likely to die within 30 days following a heart attack, which can be explained by the distinct risk factors, medical history and heart anatomy of men and women. The study, published in the current issue of the Journal of the American Medical Association, was conducted by researchers at Duke University Medical Center.
Aug. 25, 2009

About This Page
Updated: Sept. 6, 2007
Published: Sept. 6, 2007
URL: http://www.dukehealth.org/health_library/topic_centers/heart